Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
Georges Mjaess1, Fouad Aoun2, Elie Rassy3
1Department of Urology, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
Abstract:
Antibody-drug conjugates (ADCs) reflect a new promising approach in prostate cancer, even more so after the practice-changing results in other malignancies, either hematologic or solid. ADCs consist of monoclonal antibodies (mAb) targeted at specific antigens overly expressed on cancer cells compared to normal cells. A cytotoxic payload is attached to the mAb using a stable linker. In prostate cancer, PSMA, STEAP1, TROP2, CD46 and B7-H3 are antigens currently being studied as targets for ADCs. In this paper, we discuss the composition of ADCs and focus on their application and challenges as treatment options in prostate cancer.
Insights
Antibody-drug conjugates (ADCs) offer a promising new treatment for prostate cancer. These therapies utilize targeted monoclonal antibodies (mAbs) linked to cytotoxic payloads, with several antigens under investigation for ADC development.
Area of Science:
- Oncology
- Pharmacology
- Immunotherapy
Background:
- Antibody-drug conjugates (ADCs) are an emerging therapeutic strategy in oncology.
- ADCs have demonstrated significant efficacy in treating various hematologic and solid malignancies.
- Their success in other cancers prompts investigation into their potential for prostate cancer treatment.
Purpose of the Study:
- To discuss the composition and mechanism of antibody-drug conjugates (ADCs).
- To explore the application of ADCs as a treatment modality for prostate cancer.
- To identify and analyze the challenges associated with ADC therapy in prostate cancer.
Main Methods:
- Review of current literature on antibody-drug conjugates (ADCs).
- Analysis of ADC structure, including monoclonal antibodies (mAbs), linkers, and cytotoxic payloads.
- Identification of specific antigens targeted by ADCs in prostate cancer research.
Main Results:
- ADCs comprise a mAb targeting cancer-specific antigens, linked to a potent cytotoxic agent.
- Several antigens, including PSMA, STEAP1, TROP2, CD46, and B7-H3, are being investigated as ADC targets in prostate cancer.
- The targeted delivery mechanism of ADCs aims to enhance efficacy while minimizing systemic toxicity.
Conclusions:
- ADCs represent a promising therapeutic frontier for prostate cancer.
- Further research and clinical trials are necessary to overcome challenges and optimize ADC application in prostate cancer.
- Targeting specific antigens with ADCs holds potential for improved patient outcomes in prostate cancer management.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
